Summary & Overview
HCPCS Q2038: Influenza Vaccine (Fluzone), Split Virus, IM, Age 3+
HCPCS Level II code Q2038 identifies the Fluzone split-virus influenza vaccine formulation for intramuscular use in individuals aged 3 years and older. As a national vaccine product code, it is used across outpatient and ambulatory settings where seasonal influenza immunization is offered. This code is relevant to clinicians, billing staff, pharmacies, and payers because accurate coding supports vaccine tracking, claims processing, and public health reporting.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for Q2038, typical sites of service, and common billing considerations tied to administration of inactivated intramuscular influenza vaccines. The publication outlines national benchmarks and reimbursement context where available, summarizes recent policy updates affecting vaccine coverage and billing, and highlights operational points relevant to coding accuracy and claims adjudication.
The report is intended for a national audience and focuses on practical information: what the code represents, where it is used, which major payers commonly cover it, and the policy and billing factors that influence claim outcomes. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code Q2038 describes the influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone). This code covers administration of the specified inactivated influenza vaccine formulation intended for intramuscular injection in patients aged 3 years and older.
Service Type: Vaccine administration — influenza (inactivated), intramuscular formulation
Typical Site of Service: Outpatient clinics, primary care offices, pharmacies, public health clinics, and other ambulatory care settings
Clinical & Coding Specifications
Clinical Context
A 45-year-old adult presents to a primary care clinic during influenza season requesting routine immunization. The patient has no contraindications to inactivated influenza vaccine and is otherwise stable with well-controlled hypertension. The clinic nurse verifies vaccination history, screens for allergies and egg sensitivity, documents informed consent, and prepares the intramuscular influenza vaccine Q2038 (Fluzone, split virus) for administration in the deltoid. The nurse administers the vaccine, monitors the patient for 15 minutes for immediate adverse reactions, documents lot number, expiration date, and VIS edition in the electronic medical record, and updates the state immunization registry. Billing is submitted using HCPCS code Q2038 with the appropriate place of service and any necessary modifier(s). Typical workflow participants include the patient, medical assistant or nurse, supervising provider (family medicine or internal medicine), and billing staff. Typical site of service is an outpatient clinic or community immunization setting such as a pharmacy or public health clinic providing intramuscular influenza vaccination to individuals aged 3 years and older.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply and standard vaccine administration is billed without additional adjustments. |